241 related articles for article (PubMed ID: 36246617)
1. Advances and challenges of immunocheckpoint inhibitors in the treatment of primary liver cancer.
Hu M; Yao W; Shen Q
Front Genet; 2022; 13():1005658. PubMed ID: 36246617
[TBL] [Abstract][Full Text] [Related]
2. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
3. Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.
Yin X; Wu T; Lan Y; Yang W
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35075482
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.
Liu Z; Liu X; Liang J; Liu Y; Hou X; Zhang M; Li Y; Jiang X
Front Immunol; 2021; 12():765101. PubMed ID: 34675942
[TBL] [Abstract][Full Text] [Related]
5. Combined immunotherapy for hepatocellular carcinoma: How to maximize immune checkpoint blockade synergic anti-tumor effect.
Huang Y; Zhang Y; Zhang M; Zhao K; Feng L; Guan J; Dong R; Liu J; Tian D; Liu M; Xia S; Liao J
Crit Rev Oncol Hematol; 2023 Sep; 189():104070. PubMed ID: 37468083
[TBL] [Abstract][Full Text] [Related]
6. [Chinese multidisciplinary expert consensus on combined immunotherapy based on immune checkpoint inhibitors for hepatocellular carcinoma(2021 version)].
; ;
Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):636-647. PubMed ID: 34371534
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in immunotherapy for hepatocellular carcinoma.
Khan AA; Liu ZK; Xu X
Hepatobiliary Pancreat Dis Int; 2021 Dec; 20(6):511-520. PubMed ID: 34344612
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular Carcinoma Immunotherapy.
Sperandio RC; Pestana RC; Miyamura BV; Kaseb AO
Annu Rev Med; 2022 Jan; 73():267-278. PubMed ID: 34606324
[TBL] [Abstract][Full Text] [Related]
9. Current Perspectives of Immunotherapy for Hepatocellular Carcinoma.
Liu X; Lei X; Huang S; Yang X
Comb Chem High Throughput Screen; 2023 Nov; ():. PubMed ID: 38031784
[TBL] [Abstract][Full Text] [Related]
10. Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions.
Yu YX; Wang S; Liu ZN; Zhang X; Hu ZX; Dong HJ; Lu XY; Zheng JB; Cui HJ
Chin Med; 2023 May; 18(1):59. PubMed ID: 37210537
[TBL] [Abstract][Full Text] [Related]
11. [Research progress of immunotherapy alone and in combination for liver cancer].
Wu ZJL; Li K; Zhang K; Gong WD
Zhonghua Gan Zang Bing Za Zhi; 2020 Jun; 28(6):471-474. PubMed ID: 32660173
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances.
Rallis KS; Makrakis D; Ziogas IA; Tsoulfas G
World J Clin Oncol; 2022 Jun; 13(6):448-472. PubMed ID: 35949435
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects.
Makaremi S; Asadzadeh Z; Hemmat N; Baghbanzadeh A; Sgambato A; Ghorbaninezhad F; Safarpour H; Argentiero A; Brunetti O; Bernardini R; Silvestris N; Baradaran B
Biomedicines; 2021 Aug; 9(9):. PubMed ID: 34572263
[TBL] [Abstract][Full Text] [Related]
14. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Bai J; Liang P; Li Q; Feng R; Liu J
Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
[TBL] [Abstract][Full Text] [Related]
15. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.
Jin H; Qin S; He J; Xiao J; Li Q; Mao Y; Zhao L
Int J Biol Sci; 2022; 18(7):2775-2794. PubMed ID: 35541908
[TBL] [Abstract][Full Text] [Related]
16. Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Zeng P; Shen D; Zeng CH; Chang XF; Teng GJ
Curr Oncol Rep; 2020 Jun; 22(8):76. PubMed ID: 32596779
[TBL] [Abstract][Full Text] [Related]
17. Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies.
Feng GS; Hanley KL; Liang Y; Lin X
Hepatology; 2021 Jan; 73 Suppl 1(Suppl 1):104-114. PubMed ID: 32715491
[TBL] [Abstract][Full Text] [Related]
18. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
Chen Y; Hu H; Yuan X; Fan X; Zhang C
Front Immunol; 2022; 13():896752. PubMed ID: 35757756
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy.
He Y; Lu M; Che J; Chu Q; Zhang P; Chen Y
Front Oncol; 2021; 11():716844. PubMed ID: 34552872
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint and angiogenic inhibitors for the treatment of hepatocellular carcinoma: It takes two to tangle.
Sukowati C; Cabral LKD; Tiribelli C
Ann Hepatol; 2022; 27(5):100740. PubMed ID: 35809835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
